CoV2Research - May2020 - 47

One SARS-CoV-specific antibody, CR3022, was found
to bind potently with 2019-nCoV RBD as determined
by ELISA and BLI. CR3022 demonstrated a fast-on
(kon = 1.84×105 Ms-1) and slow-off (koff = 1.16×10-3
s-1) binding kinetics, resulting in a KD = 6.3 nM. To
confirm the binding result, they further measured
the binding kinetics using BLI. The whole binding kinetics assay of BLI took only 10 minutes. Researchers
concluded that CR3022 has the potential for development into a therapeutic candidate.2

Conclusion
Target binding characterization is an essential analytical step for the selection of high-affinity and
highly specific therapeutics regardless of the types
of molecules. Kinetic analysis further describes the
components of association and dissociation that
comprise the overall affinity interaction. BLI technology is helping to address real-world research questions and complete projects faster.

References
1. Daniel Wrapp, Nianshuang Wang, Kizzmekia S. Corbett,
Jory A. Goldsmith, Ching-Lin Hsieh, Olubukola Abiona,
Barney S. Graham, Jason S. McLellan. "Cryo-EM structure
of the 2019-nCoV spike in the prefusion conformation."
Science, 2020 Feb 19, pii: eabb2507. doi: 10.1126/
science.abb2507, [Epub ahead of print].
2. Tian X, Li C, Huang A, Xia S, Lu S, Shi Z, Lu L, Jiang S,
Yang Z, Wu Y, Ying T. "Potent binding of 2019 novel
coronavirus spike protein by a SARS corona¬virusspecific human monoclonal antibody." Emerg
Microbes Infect., 2020 Dec;9(1):382-385. doi:
10.1080/22221751.2020.1729069.

Additional Resources
Application Note: A fast and high precision
influenza vaccine potency assay

http://www.fortebio.com/covid19research http://www.fortebio.com/covid19research https://www.fortebio.com/sites/default/files/en/assets/app-note/fast-and-high-precision-influenza-vaccine-potency-assay.pdf

CoV2Research - May2020

Table of Contents for the Digital Edition of CoV2Research - May2020